Literature DB >> 3547570

Vaccines against encapsulated bacteria: a global agenda.

J M Griffiss, M A Apicella, B Greenwood, P H Mäkelä.   

Abstract

The World Health Organization (WHO) asked the authors to create a comprehensive program for the development of vaccines against encapsulated bacteria as a guide for the WHO Programme on Vaccine Development. The goal is a new generation of safe, inexpensive, and easily administered vaccines that are immunogenic in infancy and provide prolonged immunity in the vaccinate, secondary immunization to community members not reached in the initial application, and/or herd immunity. The approach is to capitalize on advances in molecular biology, biochemistry, and immunology, and the agenda developed addresses the five genera that cause most morbidity in less-developed areas of the world: Neisseria, Streptococcus, Staphylococcus, Haemophilus, and Pseudomonas. Three strategic areas for study are emphasized: existing polysaccharide vaccines, natural immunity and pathogenesis, and evaluation of new or speculative alternative approaches. It is hoped that this agenda will stimulate the widest possible participation in this global initiative.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3547570     DOI: 10.1093/clinids/9.1.176

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  7 in total

1.  Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates.

Authors:  A F Verheul; G J Boons; G A Van der Marel; J H Van Boom; H J Jennings; H Snippe; J Verhoef; P Hoogerhout; J T Poolman
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

Review 2.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

3.  A thymus-independent (type 1) phosphorylcholine antigen isolated from Trichinella spiralis protects mice against pneumococcal infection.

Authors:  P L Lim; W F Choy
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

4.  Characterization of the capsular polysaccharide of Burkholderia (Pseudomonas) pseudomallei 304b.

Authors:  H Masoud; M Ho; T Schollaardt; M B Perry
Journal:  J Bacteriol       Date:  1997-09       Impact factor: 3.490

5.  Nonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide-protein conjugates.

Authors:  G J Zigterman; K Schotanus; E B Ernste; G J Van Dam; M Jansze; H Snippe; J M Willers
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

6.  Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates.

Authors:  A F Verheul; A A Versteeg; M J De Reuver; M Jansze; H Snippe
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

7.  Serum opsonic capacity against Yersinia enterocolitica O:3 in yersiniosis patients with or without reactive arthritis.

Authors:  R Tertti; K Granfors; R Lahesmaa-Rantala; A Toivanen
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.